CAMBRIDGE, Mass., March 2, 2022 /PRNewswire/ -- Leap Therapeutics,
Inc. (Nasdaq: LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced that
Douglas E. Onsi, President and Chief
Executive Officer will present a corporate overview at Raymond
James Institutional Investors Conference, being held in
Orlando on March 6-9, 2022.
Leap Presentation Details:
Raymond James Annual Institutional Investors Conference
Date: Wednesday, March
9th, 2022
Time: 7:30 a.m. Eastern Time
The presentation will be webcast live and may be accessed on the
Investors page of the company's website at
https://investors.leaptx.com/, where a replay of the event will
also be available for a limited time.
About Leap Therapeutics
Leap
Therapeutics (Nasdaq: LPTX) is focused on developing targeted
and immuno-oncology therapeutics. Leap's most advanced clinical
candidate, DKN-01, is a humanized monoclonal antibody targeting the
Dickkopf-1 (DKK1) protein. DKN-01 is
in clinical trials in patients with esophagogastric, hepatobiliary,
gynecologic, and prostate cancers. Leap has entered into a
strategic partnership with BeiGene, Ltd. for the rights to develop
DKN-01 in Asia (excluding Japan), Australia,
and New Zealand. For more
information about Leap Therapeutics,
visit http://www.leaptx.com or view our public filings
with the SEC that are available via EDGAR
at http://www.sec.gov or
via https://investors.leaptx.com/.
FORWARD-LOOKING STATEMENTS
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, Section 21E of the Securities
Exchange Act of 1934, as amended, and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include Leap's expectations with
respect to the development and advancement of DKN-01, including the
initiation, timing and design of future studies, enrollment in
future studies, potential for the receipt of future option
exercise, milestone, or royalty payments from BeiGene, and other
future expectations, plans and prospects. Although Leap believes
that the expectations reflected in such forward-looking statements
are reasonable as of the date made, forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that could cause actual results to differ materially from our
expectations. Such risks and uncertainties include, but are not
limited to: that the initiation, conduct, and completion of
clinical trials, laboratory operations, manufacturing campaigns,
and other studies may be delayed, adversely affected, or impacted
by COVID-19 related issues; the accuracy of our estimates regarding
expenses, future revenues, capital requirements and needs for
financing; the outcome, cost, and timing of our product development
activities and clinical trials; the uncertain clinical development
process, including the risk that clinical trials may not have an
effective design or generate positive results; our ability to
obtain and maintain regulatory approval of our drug product
candidates; the size and growth potential of the markets for our
drug product candidates; our ability to continue obtaining and
maintaining intellectual property protection for our drug product
candidates; and other risks. Detailed information regarding factors
that may cause actual results to differ materially will be included
in Leap Therapeutics' periodic filings with the SEC,
including Leap's Annual Report on Form 10-K for the fiscal year
ended December 31, 2020, as filed with
the SEC on March 12, 2021 and as may be updated
by Leap's Quarterly Reports on Form 10-Q and the other reports Leap
files from time to time with the SEC. Any forward-looking
statement contained in this release speaks only as of its date.
Leap undertakes no obligation to update any forward-looking
statement contained in this release to reflect events or
circumstances occurring after its date or to reflect the occurrence
of unanticipated events.
CONTACT:
Douglas E.
Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-raymond-james-43rd-annual-institutional-investors-conference-301493060.html
SOURCE Leap Therapeutics, Inc.